Pacific Biosciences Of California (PACB) Total Liabilities (2010 - 2026)

Pacific Biosciences Of California's Total Liabilities history runs 17 years deep, the most recent figure standing at $780.0 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 1.41% year-over-year to $780.0 million in Q1 2026; TTM through Mar 2026 was $780.0 million, a 1.41% increase from a year earlier, with the FY2025 full-year figure at $778.7 million, up 3.3% from the prior year.
• Total Liabilities was little changed at $780.0 million in Q1 2026 per PACB's latest filing, from $778.7 million in the prior quarter.
• Across five years, Total Liabilities topped out at $1.2 billion in Q2 2023 and bottomed at $753.9 million in Q4 2024.
• The 5-year median for Total Liabilities is $1.0 billion (2024), against an average of $1.0 billion.
• Across the five-year window, Total Liabilities soared 37126.29% in 2022 and retreated 27.84% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $1.2 billion in 2022, then decreased by 13.24% to $1.0 billion in 2023, then slipped by 27.84% to $753.9 million in 2024, then advanced by 3.3% to $778.7 million in 2025, then rose by 0.16% to $780.0 million in 2026.
• Per Business Quant, the three latest PACB Total Liabilities figures stand at $780.0 million (Q1 2026), $778.7 million (Q4 2025), and $767.1 million (Q3 2025).